Panacea Biotec Limited reported earnings results for the nine months ended December 31, 2022. For the nine months, the company reported sales was INR 3,310.2 million compared to INR 5,205 million a year ago. Revenue was INR 3,676.2 million compared to INR 5,274.2 million a year ago.

Net loss was INR 210.7 million compared to INR 1,595.6 million a year ago. Basic loss per share from continuing operations was INR 3.44 compared to INR 26.05 a year ago. Diluted loss per share from continuing operations was INR 3.44 compared to INR 26.05 a year ago.